JPMorgan analyst Andrew Hanover expects Cooper Companies' (COO) agreement to purchase Teva Pharmaceuticals' (TEVA) Paragard Intrauterine Device to garner a mixed reaction from investors. It will be hard for the 7% of accretion in FY18 "to be enough," since the stock's 45% rally year-to-date is likely driven by investors focused on its consumer-focused CVI business, and this deal does not fit that thesis, Hanover tells investors in a research note. The analyst keeps a Neutral rating on Cooper with a $235 price target.

Teva Pharmaceuticals announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body movements known as chorea - a symptom that can have a significant impact on daily activities like eating or talking.3-5 These data are being presented at the 2024 American Academy of Neurology AAN Annual Meeting. "90% of HD patients experience chorea,3,4 so it's important for patients to have a treatment option that not only helps address symptoms, but helps provide a positive patient experience," said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. "We remain committed to exploring ways to evolve the AUSTEDO treatment experience to meet the needs of the HD community, and these latest real-world data reinforce the role of the 4-week Titration Kit for AUSTEDO in empowering patients with HD chorea to find their optimal dose, adhere consistently to their treatment plan, and achieve effective outcomes."